Technology

A novel non-hormonal male contraceptive drug that can be taken orally, is effective within hours and is easily reversible is being developed at King's. The contraceptive method uses a new approach directed towards the inhibition of sperm emission through drug-induced control of vas deferens contractility. KCL researchers have identified the mechanism of contraceptive action based on their research on side effects of known drugs. A class of compounds that replicate the effects of the known compounds has been identified and new drugs designed.

Market

Current female oral contraceptive market valued at $4.3 billion with 100 million users worldwide. At present there are no pharmacological male contraceptive alternatives on the market. Male willingness to use novel contraceptives (other than condoms or vasectomy) has been recorded at 50% in the USA and at an average of 60% in European countries (Martin et al, 2000; Heinemann et al 2005).

Benefits

The King's contraceptive approach inhibits sperm emission without affecting penile erection, orgasmic sensation, hormonal balance or blood pressure.

Non-invasive, unlike occlusive contraceptive devices currently in clinical development which involve invasive procedures and medical expertise for insertion and removal.

Unlike hormonal contraceptives, where there are concerns over route of administration (injection/implant), lag time to contraceptive efficacy/ reversibility and ethnic differences in efficacy.

Development

New drugs have been synthesized which will be tested in ex vivo assays using human vas deferens samples and in in vivo models.

UK  & PCT patent applications has been filed.

Licensing/collaboration partners are sought for this technology.